211 related articles for article (PubMed ID: 38239718)
1. Bioinformatics procedure for investigating senolytic (anti-aging) agents: A digital signal processing technique.
Nwankwo N; Okafor I
Aging Med (Milton); 2023 Dec; 6(4):338-346. PubMed ID: 38239718
[TBL] [Abstract][Full Text] [Related]
2. Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells.
Le HH; Cinaroglu SS; Manalo EC; Ors A; Gomes MM; Duan Sahbaz B; Bonic K; Origel Marmolejo CA; Quentel A; Plaut JS; Kawashima TE; Ozdemir ES; Malhotra SV; Ahiska Y; Sezerman U; Bayram Akcapinar G; Saldivar JC; Timucin E; Fischer JM
EBioMedicine; 2021 Nov; 73():103646. PubMed ID: 34689087
[TBL] [Abstract][Full Text] [Related]
3. Biophysical investigation of the dual binding surfaces of human transcription factors FOXO4 and p53.
Kim J; Ahn D; Park CJ
FEBS J; 2022 Jun; 289(11):3163-3182. PubMed ID: 34954873
[TBL] [Abstract][Full Text] [Related]
4. Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From
Huang Y; He Y; Makarcyzk MJ; Lin H
Front Bioeng Biotechnol; 2021; 9():677576. PubMed ID: 33996787
[TBL] [Abstract][Full Text] [Related]
5. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice.
Zhang C; Xie Y; Chen H; Lv L; Yao J; Zhang M; Xia K; Feng X; Li Y; Liang X; Sun X; Deng C; Liu G
Aging (Albany NY); 2020 Jan; 12(2):1272-1284. PubMed ID: 31959736
[TBL] [Abstract][Full Text] [Related]
6. FOXO4 peptide targets myofibroblast ameliorates bleomycin-induced pulmonary fibrosis in mice through ECM-receptor interaction pathway.
Han X; Yuan T; Zhang J; Shi Y; Li D; Dong Y; Fan S
J Cell Mol Med; 2022 Jun; 26(11):3269-3280. PubMed ID: 35510614
[TBL] [Abstract][Full Text] [Related]
7. FOXO4 Transactivation Domain Interaction with Forkhead DNA Binding Domain and Effect on Selective DNA Recognition for Transcription Initiation.
Kim J; Ahn D; Park CJ
J Mol Biol; 2021 Feb; 433(4):166808. PubMed ID: 33450250
[TBL] [Abstract][Full Text] [Related]
8. Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span.
Robbins PD; Jurk D; Khosla S; Kirkland JL; LeBrasseur NK; Miller JD; Passos JF; Pignolo RJ; Tchkonia T; Niedernhofer LJ
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():779-803. PubMed ID: 32997601
[TBL] [Abstract][Full Text] [Related]
9. National Institute on Aging Workshop: Repurposing Drugs or Dietary Supplements for Their Senolytic or Senomorphic Effects: Considerations for Clinical Trials.
Romashkan S; Chang H; Hadley EC
J Gerontol A Biol Sci Med Sci; 2021 May; 76(6):1144-1152. PubMed ID: 33528569
[TBL] [Abstract][Full Text] [Related]
10. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics.
Zhang L; Pitcher LE; Prahalad V; Niedernhofer LJ; Robbins PD
FEBS J; 2023 Mar; 290(5):1362-1383. PubMed ID: 35015337
[TBL] [Abstract][Full Text] [Related]
11. Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies.
Khalil R; Diab-Assaf M; Lemaitre JM
Cells; 2023 Mar; 12(6):. PubMed ID: 36980256
[TBL] [Abstract][Full Text] [Related]
12. Short senolytic or senostatic interventions rescue progression of radiation-induced frailty and premature ageing in mice.
Fielder E; Wan T; Alimohammadiha G; Ishaq A; Low E; Weigand BM; Kelly G; Parker C; Griffin B; Jurk D; Korolchuk VI; von Zglinicki T; Miwa S
Elife; 2022 May; 11():. PubMed ID: 35507395
[TBL] [Abstract][Full Text] [Related]
13. Why Senescent Cells Are Resistant to Apoptosis: An Insight for Senolytic Development.
Hu L; Li H; Zi M; Li W; Liu J; Yang Y; Zhou D; Kong QP; Zhang Y; He Y
Front Cell Dev Biol; 2022; 10():822816. PubMed ID: 35252191
[TBL] [Abstract][Full Text] [Related]
14. Cellular senescence in the aging and diseased kidney.
Valentijn FA; Falke LL; Nguyen TQ; Goldschmeding R
J Cell Commun Signal; 2018 Mar; 12(1):69-82. PubMed ID: 29260442
[TBL] [Abstract][Full Text] [Related]
15. Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseases.
Lagoumtzi SM; Chondrogianni N
Free Radic Biol Med; 2021 Aug; 171():169-190. PubMed ID: 33989756
[TBL] [Abstract][Full Text] [Related]
16. A study of the molecular mechanism of quercetin and dasatinib combination as senolytic in alleviating age-related and kidney diseases.
Alharbi KS; Afzal O; Altamimi ASA; Almalki WH; Kazmi I; Al-Abbasi FA; Alzarea SI; Makeen HA; Albratty M
J Food Biochem; 2022 Dec; 46(12):e14471. PubMed ID: 36268851
[TBL] [Abstract][Full Text] [Related]
17. Bone-targeted delivery of senolytics to eliminate senescent cells increases bone formation in senile osteoporosis.
Xing X; Tang Q; Zou J; Huang H; Yang J; Gao X; Xu X; Ma S; Li M; Liang C; Tan L; Liao L; Tian W
Acta Biomater; 2023 Feb; 157():352-366. PubMed ID: 36470392
[TBL] [Abstract][Full Text] [Related]
18. Supramolecular Senolytics via Intracellular Oligomerization of Peptides in Response to Elevated Reactive Oxygen Species Levels in Aging Cells.
Kim S; Chae JB; Kim D; Park CW; Sim Y; Lee H; Park G; Lee J; Hong S; Jana B; Kim C; Chung H; Ryu JH
J Am Chem Soc; 2023 Oct; 145(40):21991-22008. PubMed ID: 37664981
[TBL] [Abstract][Full Text] [Related]
19. Exploring the fuzzy border between senolytics and senomorphics with chemoinformatics and systems pharmacology.
Olascoaga-Del Angel KS; Gutierrez H; Königsberg M; Pérez-Villanueva J; López-Diazguerrero NE
Biogerontology; 2022 Aug; 23(4):453-471. PubMed ID: 35781578
[TBL] [Abstract][Full Text] [Related]
20. From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs.
L'Hôte V; Mann C; Thuret JY
Open Biol; 2022 Sep; 12(9):220171. PubMed ID: 36128715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
